Published in Neoplasia on June 01, 1999
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia (2000) 2.84
Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging (2006) 2.69
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A (2000) 2.49
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (2005) 2.17
Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia (1999) 2.16
Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging (2006) 1.91
Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res (2009) 1.89
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia (2000) 1.72
Extracranial applications of diffusion-weighted magnetic resonance imaging. Eur Radiol (2007) 1.55
Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer (2006) 1.54
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia (2005) 1.45
Diffusion imaging for therapy response assessment of brain tumor. Neuroimaging Clin N Am (2009) 1.38
Amide proton transfer imaging of the breast at 3 T: establishing reproducibility and possible feasibility assessing chemotherapy response. Magn Reson Med (2012) 1.35
Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA (2004) 1.33
Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia (2004) 1.32
Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia (2002) 1.32
Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology (2008) 1.20
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res (2008) 1.17
Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol (2008) 1.09
Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice. Neoplasia (2007) 1.08
Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging (2011) 1.08
Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. Clin Cancer Res (2008) 1.06
Imaging response to systemic therapy for bone metastases. Eur Radiol (2009) 0.99
Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study. Br J Radiol (2009) 0.96
Task-based evaluation of segmentation algorithms for diffusion-weighted MRI without using a gold standard. Phys Med Biol (2012) 0.93
Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J Oncol (2010) 0.93
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging (2012) 0.92
Incorporation of diffusion-weighted magnetic resonance imaging data into a simple mathematical model of tumor growth. Phys Med Biol (2012) 0.92
Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res (2010) 0.90
The role of perfusion effects in monitoring of chemoradiotherapy of rectal carcinoma using diffusion-weighted imaging. Cancer Imaging (2013) 0.89
Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem (2009) 0.88
Early prediction of the response of breast tumors to neoadjuvant chemotherapy using quantitative MRI and machine learning. AMIA Annu Symp Proc (2011) 0.88
Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer. Magn Reson Imaging (2013) 0.86
Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy. PLoS One (2013) 0.86
Assessment of multiexponential diffusion features as MRI cancer therapy response metrics. Magn Reson Med (2010) 0.85
Motion correction in diffusion-weighted MRI of the breast at 3T. J Magn Reson Imaging (2011) 0.85
Diffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy. Acad Radiol (2011) 0.84
MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging (2009) 0.83
Longitudinal diffusion tensor imaging in a rat brain glioma model. NMR Biomed (2008) 0.83
Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy. PLoS One (2015) 0.83
Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy. J Magn Reson Imaging (2013) 0.82
High-field small animal magnetic resonance oncology studies. Phys Med Biol (2013) 0.81
A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. Br J Radiol (2011) 0.81
Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma. PLoS One (2014) 0.78
Diffusion-weighted magnetic resonance imaging for assessment after neoadjuvant chemotherapy in breast cancer, based on morphological concepts. Oncol Lett (2010) 0.77
Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma. J Zhejiang Univ Sci B (2014) 0.76
Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy. Neoplasia (2016) 0.75
The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in ovarian tumour xenografts. Sci Rep (2017) 0.75
Imaging across the life span: innovations in imaging and therapy for gynecologic cancer. Radiographics (2014) 0.75
Monitoring the Effect of Docetaxel Treatment in MCF7 Xenografts Using Multimodal In Vivo and Ex Vivo Magnetic Resonance Methods, Histopathology, and Gene Expression. Transl Oncol (2010) 0.75
Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B (1996) 19.47
Early detection of regional cerebral ischemia in cats: comparison of diffusion- and T2-weighted MRI and spectroscopy. Magn Reson Med (1990) 4.88
Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol (1995) 3.13
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res (1997) 2.96
Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am J Neuroradiol (1990) 2.80
Time-dependent diffusion of water in a biological model system. Proc Natl Acad Sci U S A (1994) 2.59
The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res (1996) 2.57
Theoretical model for water diffusion in tissues. Magn Reson Med (1995) 2.43
Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer (1996) 2.20
Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res (1997) 1.97
Water diffusion and acute stroke. Magn Reson Med (1994) 1.77
Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A (1994) 1.75
Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res (1998) 1.52
Magnetic Resonance Imaging and Spectroscopy: Application to Experimental Neuro-Oncology. Q Magn Reson Biol Med (1) 1.43
Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. Cancer Res (1998) 1.33
Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer (1991) 1.31
Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep (1987) 1.25
Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol (1997) 1.20
Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res (1998) 1.15
Characterization of cell volume loss in CEM-C7A cells during dexamethasone-induced apoptosis. Am J Physiol (1996) 1.15
Imaging of the apparent diffusion coefficient for the evaluation of cerebral metabolic recovery after cardiac arrest. Magn Reson Imaging (1995) 1.03
P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim Biophys Acta (1992) 1.02
Paclitaxel pharmacology and other tumor types. Semin Oncol (1997) 1.02
Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res (1998) 0.93
Hemodialysis increases apparent diffusion coefficient of brain water in nephrectomized rats measured by isotropic diffusion-weighted magnetic resonance imaging. J Clin Invest (1996) 0.92
Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep (1998) 0.89
Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur J Cancer (1997) 0.89
Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors. Pharm Res (1998) 0.86
Cytostatic and apoptotic effects of paclitaxel in human breast tumors. Cancer Chemother Pharmacol (1998) 0.86
Magnetic resonance imaging of lipid deposits in human atheroma via a stimulated-echo diffusion-weighted technique. Magn Reson Med (1991) 0.82
Changes in the epithelium of the cervix uteri. A study by the panel of pathologists engaged in the survey of carcinoma in situ carried out by the Royal College of Obstetricians and Gynaecologists. J Obstet Gynaecol Br Commonw (1966) 5.13
The histology and cytology of changes in the epithelium of the cervix uteri. J Clin Pathol (1969) 4.25
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol (1989) 2.89
Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis (1996) 2.44
Determination of cell number in monolayer cultures. Anal Biochem (1986) 2.43
Nucleotide sequence of 4.5 S ribonucleic acid of Novikoff hepatoma cell nuclei. J Biol Chem (1972) 2.30
New duplication-generating inversions in Neurospora. Can J Genet Cytol (1969) 2.30
A pericentric inversion in Neurospora, with unstable duplication progeny. Genetics (1967) 2.25
Spontaneous calcium release from inositol trisphosphate-sensitive calcium stores. Nature (1991) 2.16
Use of lipid composition and metabolism to examine structure and activity of estuarine detrital microflora. Appl Environ Microbiol (1977) 2.12
Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer (2007) 2.00
New markers and map sequences in Neurospora crassa, with a description of mapping by duplication coverage, and of multiple translocation stocks for testing linkage. Genetica (1969) 1.97
A non-capacitative pathway activated by arachidonic acid is the major Ca2+ entry mechanism in rat A7r5 smooth muscle cells stimulated with low concentrations of vasopressin. J Physiol (1999) 1.94
Isolation and characterization of protein A24, a "histone-like" non-histone chromosomal protein. J Biol Chem (1975) 1.91
T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum (2002) 1.88
In vivo imaging of extracellular pH using 1H MRSI. Magn Reson Med (1999) 1.86
31P NMR studies of intracellular pH and phosphate metabolism during cell division cycle of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1981) 1.84
Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res (2000) 1.81
Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer (1999) 1.79
Evidence suggesting that a novel guanine nucleotide regulatory protein couples receptors to phospholipase C in exocrine pancreas. Biochem J (1986) 1.74
Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia (2000) 1.72
Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol (2003) 1.68
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1995) 1.67
Cooperative activation of IP3 receptors by sequential binding of IP3 and Ca2+ safeguards against spontaneous activity. Curr Biol (1997) 1.63
In vivo carbon-13 nuclear magnetic resonance studies of mammals. Science (1981) 1.61
Effects of Ca2+ chelators on purified inositol 1,4,5-trisphosphate (InsP3) receptors and InsP3-stimulated Ca2+ mobilization. J Biol Chem (1993) 1.59
Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol (1993) 1.57
Luminal Ca2+ increases the sensitivity of Ca2+ stores to inositol 1,4,5-trisphosphate. Mol Pharmacol (1992) 1.56
Differential regulation of types-1 and -3 inositol trisphosphate receptors by cytosolic Ca2+. Biochem J (1997) 1.49
All-or-nothing Ca2+ mobilization from the intracellular stores of single histamine-stimulated HeLa cells. J Physiol (1992) 1.49
pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol (1999) 1.48
The management of dysplasia, carcinoma in situ and microcarcinoma of the cervix. J Obstet Gynaecol Br Commonw (1973) 1.48
Two calcium-binding sites mediate the interconversion of liver inositol 1,4,5-trisphosphate receptors between three conformational states. Biochem J (1994) 1.47
Vasopressin stimulation of Ca2+ mobilization, two bivalent cation entry pathways and Ca2+ efflux in A7r5 rat smooth muscle cells. J Physiol (1995) 1.45
The thiol reagent, thimerosal, evokes Ca2+ spikes in HeLa cells by sensitizing the inositol 1,4,5-trisphosphate receptor. J Biol Chem (1992) 1.44
Combined vascular and extracellular pH imaging of solid tumors. NMR Biomed (2002) 1.44
Quantal Ca2+ mobilization stimulated by inositol 1,4,5-trisphosphate in permeabilized hepatocytes. Biochem J (1991) 1.42
Calcium and inositol trisphosphate receptors. J Membr Biol (1995) 1.41
Lateral inhibition of inositol 1,4,5-trisphosphate receptors by cytosolic Ca(2+). Curr Biol (1999) 1.39
Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol (1999) 1.38
High-resolution diffusion imaging with DIFRAD-FSE (diffusion-weighted radial acquisition of data with fast spin-echo) MRI. Magn Reson Med (1999) 1.36
Luminal Ca2+ promoting spontaneous Ca2+ release from inositol trisphosphate-sensitive stores in rat hepatocytes. J Physiol (1992) 1.35
Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells. Cancer Res (1996) 1.33
Intracellular pH changes during the cell cycle in Tetrahymena. J Cell Physiol (1979) 1.30
Liver inositol, 1,4,5-trisphosphate-binding sites are the Ca2(+)-mobilizing receptors. Biochem J (1990) 1.26
Spontaneous Ca2+ spiking in a vascular smooth muscle cell line is independent of the release of intracellular Ca2+ stores. J Biol Chem (1993) 1.24
Two-dimensional electrophoresis of proteins of citric acid nuclei prepared with aid of a Tissumizer. Exp Cell Res (1973) 1.23
Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst (1992) 1.23
Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res (2001) 1.22
Biphasic effects of cytosolic Ca2+ on Ins(1,4,5)P3-stimulated Ca2+ mobilization in hepatocytes. J Biol Chem (1993) 1.22
Ca2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptors. Mol Pharmacol (1994) 1.21
Structural analysis of the glycine-rich, arginine-rich histone. 3. Sequence of the amino-terminal half of the molecule containing the modified lysine residues and the total sequence. J Biol Chem (1969) 1.21
Simultaneous measurement of intracellular pH and Ca2+ using the fluorescence of SNARF-1 and fura-2. Am J Physiol (1991) 1.20
Ca2+-independent inhibition of inositol trisphosphate receptors by calmodulin: redistribution of calmodulin as a possible means of regulating Ca2+ mobilization. Proc Natl Acad Sci U S A (1997) 1.20
Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol (1997) 1.20
In vivo phosphorus-31 nuclear magnetic resonance reveals lowered ATP during heat shock of Tetrahymena. Science (1983) 1.18
Reconstruction of MR images from data acquired on a general nonregular grid by pseudoinverse calculation. IEEE Trans Med Imaging (2000) 1.18
pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol (1999) 1.16
A novel role for calmodulin: Ca2+-independent inhibition of type-1 inositol trisphosphate receptors. Biochem J (1998) 1.15
31P nuclear magnetic resonance evidence for the regulation of intracellular pH by Ehrlich ascites tumor cells. J Cell Biol (1982) 1.15
Rapid activation and partial inactivation of inositol trisphosphate receptors by inositol trisphosphate. Biochemistry (1998) 1.14
The B lymphocyte calcium response to anti-Ig is diminished by membrane immunoglobulin cross-linkage to the Fc gamma receptor. J Immunol (1987) 1.13
Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia (2001) 1.13
Size of the inositol 1,4,5-trisphosphate-sensitive calcium pool in guinea-pig hepatocytes. Biochem J (1985) 1.12
Ca2+-calmodulin inhibits Ca2+ release mediated by type-1, -2 and -3 inositol trisphosphate receptors. Biochem J (2000) 1.12
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol (1993) 1.12
Molecular target sizes of inositol 1,4,5-trisphosphate receptors in liver and cerebellum. Biochem J (1990) 1.07
Determination of intracellular pH of BALB/c-3T3 cells using the fluorescence of pyranine. Anal Biochem (1987) 1.07
Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magn Reson Med (1999) 1.03
Selective recognition of inositol phosphates by subtypes of the inositol trisphosphate receptor. Biochem J (2001) 1.03
Disaccharide polyphosphates based upon adenophostin A activate hepatic D-myo-inositol 1,4,5-trisphosphate receptors. Biochemistry (1997) 1.03
Estimations of intra- and extracellular volume and pH by 31P magnetic resonance spectroscopy: effect of therapy on RIF-1 tumours. Br J Cancer (1998) 1.02
Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the Metabolic Boyden Chamber. Neoplasia (2000) 1.01
Parathyroid hormone controls the size of the intracellular Ca(2+) stores available to receptors linked to inositol trisphosphate formation. J Biol Chem (2000) 1.01
The fractionation of arginine-rich histones from fetal calf thymus by exclusion chromatography. J Biol Chem (1967) 1.00
Type 3 inositol trisphosphate receptors in RINm5F cells are biphasically regulated by cytosolic Ca2+ and mediate quantal Ca2+ mobilization. Biochem J (1999) 1.00
Caffeine-stimulated Ca2+ release from the intracellular stores of hepatocytes is not mediated by ryanodine receptors. Biochem J (1993) 1.00
Delayed autoregulation of the Ca2+ signals resulting from capacitative Ca2+ entry in bovine pulmonary artery endothelial cells. J Physiol (1997) 1.00
Regulation of inositol trisphosphate receptors by luminal Ca2+ contributes to quantal Ca2+ mobilization. EMBO J (1996) 0.99
A guanine nucleotide-dependent regulatory protein couples substance P receptors to phospholipase C in rat parotid gland. Biochem Biophys Res Commun (1986) 0.98
Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels. Mol Pharmacol (1996) 0.98
Differences in chromatin proteins of growing and non-growing tissues. Exp Cell Res (1975) 0.98
pH and chemotherapy. Novartis Found Symp (2001) 0.98
Extracellular heavy-metal ions stimulate Ca2+ mobilization in hepatocytes. Biochem J (1999) 0.97
Analysis and comparison of motion-correction techniques in diffusion-weighted imaging. J Magn Reson Imaging (1997) 0.97
Characterization of a diamine exporter in Chinese hamster ovary cells and identification of specific polyamine substrates. J Biol Chem (1997) 0.97
2,5-Di-(tert-butyl)-1,4-benzohydroquinone mobilizes inositol 1,4,5-trisphosphate-sensitive and -insensitive Ca2+ stores. FEBS Lett (1990) 0.96
Prolonged exposure to inositol 1,4,5-trisphosphate does not cause intrinsic desensitization of the intracellular Ca(2+)-mobilizing receptor. J Biol Chem (1992) 0.95
Attributes of a good practicing physician. J Med Educ (1971) 0.95
Endogenous heavy metal ions perturb fura-2 measurements of basal and hormone-evoked Ca2+ signals. Biophys J (1996) 0.95
Regulation of inositol 1,4,5-trisphosphate receptors. J Exp Biol (1993) 0.94
A fetal protein in chromatin of Novikoff hepatoma and Walker 256 carcinosarcoma tumors that is absent from normal and regenerating rat liver. Proc Natl Acad Sci U S A (1976) 0.94
Incremental Ca2+ mobilization by inositol trisphosphate receptors is unlikely to be mediated by their desensitization or regulation by luminal or cytosolic Ca2+. Biochem J (1997) 0.93
Structural determinants of adenophostin A activity at inositol trisphosphate receptors. Mol Pharmacol (2001) 0.93
The physiological environment in cancer vascularization, invasion and metastasis. Novartis Found Symp (2001) 0.92